drugset
drugset / Trial / NCT03161405

A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-906 in Healthy Participants

NCT03161405 ↗

Phase 1 Completed 12 enrolled Millennium Pharmaceuticals, Inc.
NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to evaluate the effect of the potent cytochrome P-450 (CYP) 3A4 inhibitor (itraconazole) on the single-dose PK of oral TAK-906 maleate.

Timeline

Start
2017-06-05
Primary completion
2017-07-02
Completion
2017-07-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 200 mg Oral
Subject Trazpiroben Small molecule 25 mg Oral

Indications

No indication recorded.